Cambridge Investment Research Advisors Inc. Has $787,000 Holdings in TransMedics Group, Inc. (NASDAQ:TMDX)

Cambridge Investment Research Advisors Inc. boosted its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 65.9% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 11,692 shares of the company's stock after acquiring an additional 4,643 shares during the period. Cambridge Investment Research Advisors Inc.'s holdings in TransMedics Group were worth $787,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. NBC Securities Inc. bought a new position in TransMedics Group during the first quarter worth about $25,000. Atlas Capital Advisors Inc. bought a new stake in shares of TransMedics Group in the fourth quarter valued at about $31,000. AlphaQuest LLC bought a new stake in shares of TransMedics Group in the fourth quarter valued at about $52,000. Rakuten Securities Inc. lifted its holdings in shares of TransMedics Group by 68.3% in the fourth quarter. Rakuten Securities Inc. now owns 1,355 shares of the company's stock valued at $84,000 after purchasing an additional 550 shares in the last quarter. Finally, Sava Infond d.o.o. bought a new stake in shares of TransMedics Group in the fourth quarter valued at about $94,000. 99.67% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

TMDX has been the topic of a number of research reports. Needham & Company LLC restated a "hold" rating on shares of TransMedics Group in a report on Tuesday, June 17th. Piper Sandler restated an "overweight" rating and issued a $145.00 price target (up from $125.00) on shares of TransMedics Group in a report on Wednesday, June 4th. Finally, Oppenheimer boosted their price target on TransMedics Group from $130.00 to $150.00 and gave the company an "outperform" rating in a report on Tuesday, June 17th. Three investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $127.33.

TransMedics Group Stock Down 1.3%

Shares of NASDAQ:TMDX traded down $1.63 during midday trading on Thursday, reaching $124.78. The company had a trading volume of 650,538 shares, compared to its average volume of 1,366,264. The company has a quick ratio of 8.32, a current ratio of 9.10 and a debt-to-equity ratio of 1.92. The business's 50 day moving average price is $124.35 and its 200 day moving average price is $89.70. The stock has a market cap of $4.22 billion, a PE ratio of 91.75 and a beta of 2.06. TransMedics Group, Inc. has a 1-year low of $55.00 and a 1-year high of $177.37.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported $0.70 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.29 by $0.41. The business had revenue of $143.54 million for the quarter, compared to the consensus estimate of $123.39 million. TransMedics Group had a return on equity of 21.88% and a net margin of 10.03%. TransMedics Group's quarterly revenue was up 48.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.35 earnings per share. Research analysts forecast that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.

Insiders Place Their Bets

In other TransMedics Group news, insider Anil P. Ranganath sold 686 shares of the business's stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $139.80, for a total transaction of $95,902.80. Following the transaction, the insider owned 13,955 shares of the company's stock, valued at $1,950,909. The trade was a 4.69% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director David Weill sold 732 shares of the business's stock in a transaction that occurred on Friday, May 23rd. The stock was sold at an average price of $123.88, for a total value of $90,680.16. Following the transaction, the director directly owned 12,134 shares in the company, valued at approximately $1,503,159.92. This trade represents a 5.69% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 12,418 shares of company stock valued at $1,512,613 over the last 90 days. 7.00% of the stock is currently owned by insiders.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.